Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia (scholarly article by Marius Lahti et al published 12 March 2012 in Psychological Medicine)

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

Q28036762

Quality of medical care and excess mortality in older patients with mental disorders

Q28184670

Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study

Q28220276

Severe mental illness and mortality of hospitalized ACS patients in the VHA

Q28221749

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline

Q31051209

The validation of the Finnish Hospital Discharge Register and Causes of Death Register data on stroke diagnoses

Q31115680

Validation of stroke diagnosis in the National Hospital Discharge Register and the Register of Causes of Death in Finland

Q33594762

Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors

Q33663582

Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London

Q33911053

Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis

Q33917942

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

Q34018491

Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants

Q34123160

Review: Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?

Q34183495

Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis

Q34183529

Lifetime prevalence of psychotic and bipolar I disorders in a general population

Q34596831

Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Q34623350

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.

Q34631699

Cause-specific excess deaths associated with underweight, overweight, and obesity

Q34711194

Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

Q35016170

Cigarette smoking and mortality risk in people with schizophrenia

Q35065406

Twenty-five year mortality of a community cohort with schizophrenia

Q36028183

Schizophrenia and increased risks of cardiovascular disease

Q36336286

Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension

Q36730924

Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators

Q36860419

The validity of hospital discharge register data on coronary heart disease in Finland

Q36876575

Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder

Q37542726

The validity of schizophrenia diagnosis in the Finnish Hospital Discharge Register: findings from a 10-year birth cohort sample

Q40073231

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs

Q43202669

The fetal and childhood growth of persons who develop type 2 diabetes

Q44305968

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

Q46683011

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

Q46810855

The validity of death certificates: routine validation of death certification and its effects on mortality statistics.

Q50666824

Accuracy of register- and record-based bipolar I disorder diagnoses in Finland; a study of twins.

Q51974417

Mental disorders and use of cardiovascular procedures after myocardial infarction.

Q51977736

Accuracy of register-based schizophrenia diagnoses in a genetic study.

Q51997471

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

Q55054009

Infant Growth and Stroke in Adult Life

Q57403019

Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare

Q58192662

Growth and living conditions in childhood and hypertension in adult life: a longitudinal study

Q58993682

Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder

Q79459262

Mortality in patients with schizophrenia

Q84864748

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

circulatory system

Q11068

schizophrenia

Q41112

P304

page(s)

2275-2285

P577

publication date

2012-03-12

P1433

published in

Psychological Medicine

Q7256364

P1476

title

Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia

P478

volume

Reverse relations

cites work (P2860)

Q86591610	20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)
Q38262426	A double-edged sword: review of the interplay between physical health and mental health.
Q34661499	Almost all antipsychotics result in weight gain: a meta-analysis
Q38473090	Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications.
Q46428984	Association between concomitant psychiatric drug use, and patients' beliefs about and persistence with chronic cardiovascular medication
Q47560404	Bivariate Genome-Wide Association Study of Depressive Symptoms with Type 2 Diabetes and Quantitative Glycemic Traits
Q36198276	Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study
Q46158848	Cardiovascular drug use and mortality in patients with schizophrenia or bipolar disorder: a Danish population-based study
Q39837994	Clinically useful predictors for premature mortality among psychiatric patients visiting a psychiatric emergency room
Q37231225	Detection of subclinical atherosclerosis and diastolic dysfunction in patients with schizophrenia
Q89545549	Diagnostic tests and treatment procedures performed prior to cardiovascular death in individuals with severe mental illness
Q87911567	Disparities in the management of cardiovascular risk factors in patients with psychiatric disorders: a systematic review and meta-analysis
Q90136385	Early environmental factors and somatic comorbidity in schizophrenia and nonschizophrenic psychoses: A 50-year follow-up of the Northern Finland Birth Cohort 1966
Q58725597	Long-term psychiatric inpatients' perspectives on weight gain, body satisfaction, diet and physical activity: a mixed methods study
Q33762540	Mortality in schizophrenia: clinical and serological predictors
Q89824857	Mortality, Revascularization, and Cardioprotective Pharmacotherapy After Acute Coronary Syndrome in Patients With Psychotic Disorders: A Population-Based Cohort Study
Q39021125	Patients with psychiatric comorbidity can safely undergo bariatric surgery with equivalent success
Q33670588	Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls
Q38151984	Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins
Q37486960	QTc Prolongation in Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation Antipsychotics
Q90672013	Retinal correlates of psychiatric disorders
Q35537155	Retinal microvessels reflect familial vulnerability to psychotic symptoms: A comparison of twins discordant for psychotic symptoms and controls
Q47649889	Risperidone-induced metabolic dysfunction is attenuated by Curcuma longa extract administration in mice.
Q60047581	The Association of Pre-stroke Psychosis and Post-stroke Levels of Health, Resource Utilization, and Care Process: A Register-Based Study
Q47694273	The Meaning of the Lived Experience of Lifestyle Changes for People with Severe Mental Illness
Q90216691	The Predictive Value of Endothelial Inflammatory Markers in the Onset of Schizophrenia
Q50658512	The prevalence of metabolic syndrome in people with severe mental illness: a mediation analysis.
Q38401379	Transformation of excess mortality in people with schizophrenia and bipolar disorder in Taiwan
Q35673737	Twenty Years of Schizophrenia Research in the Northern Finland Birth Cohort 1966: A Systematic Review
Q92190102	Undiagnosed cardiovascular disease prior to cardiovascular death in individuals with severe mental illness
Q55023835	What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

P356	DOI	10.1017/S0033291712000396
P698	PubMed publication ID	22405504